Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 7 min read

ARA-290: mechanism of action

ARA-290 is a non-hematopoietic erythropoietin analogue peptide studied for its interaction with the innate repair receptor. This page summarises the receptor pharmacology and the preclinical and clinical research models

peptides-pro Editorial

ARA-290 is a synthetic peptide developed as a non-hematopoietic analogue of erythropoietin (EPO). It is also referred to in the literature and in trial registries as ARA 290, and it belongs to the class of compounds described as innate repair receptor (IRR) ligands — peptides engineered to engage the EPO receptor heteromer without stimulating erythropoiesis. The evidence block supplied for this page does not give a sequence, molecular formula or molecular weight for the compound, so none are stated here. What the evidence does establish is the pharmacological premise: ARA-290 is a peptide that does not have the effects of EPO on blood cells but may still act on brain function [6], and it is described in a trial record as a new class of compound whose brief interaction with the innate repair receptor results in anti-apoptotic and anti-inflammatory activities across a range of cells, tissues and organs [4].

The pathway at the centre of the work is the erythropoietin/erythropoietin receptor (EPO/EPOR) signalling axis, and in particular the heteromeric receptor complex through which the non-hematopoietic arm of that axis is thought to operate [4][9].

Research Studies

ARA-290 and the innate repair receptor in sarcoidosis-associated small fiber neuropathy

The clearest statement of the proposed mechanism in the supplied evidence comes from a registered trial in subjects with sarcoidosis and symptoms of small fiber neuropathy. That record describes ARA-290 as a compound whose brief interaction with the innate repair receptor produces anti-apoptotic and anti-inflammatory activity in a wide range of cells, tissues and organs, activating repair mechanisms and accelerating healing, including nerve damage associated with sarcoidosis [4]. In the study itself, participants were to receive ARA-290 or placebo by subcutaneous injection daily for 28 days, with safety monitoring alongside assessment of neuropathic symptoms [4]. This is a clinical protocol record rather than a report of completed outcomes, and the mechanism language in it is the sponsor's framing of the rationale rather than a measured result.

ARA-290 and glycaemic control in prediabetes and type 2 diabetes

A separate registered trial was designed to test whether a non-hematopoietic erythropoietin analogue exerts beneficial effects on blood glucose levels and insulin secretion in persons with prediabetes — impaired glucose tolerance or impaired fasting glucose — or drug-naive type 2 diabetes [5]. The same protocol lists insulin sensitivity and serum levels of inflammatory agents such as cytokines as secondary evaluations, with safety followed through haematology, kidney and liver function and lipid parameters [5]. The rationale connects to the broader metabolic literature on EPO, which reports that EPO influences glucose and fat metabolism in adipose tissue, skeletal muscle and the liver, enhances lipolysis and inhibits lipogenic gene expression in white and brown adipose tissue and skeletal muscle, and plays a role in maintaining metabolic homeostasis and regulating fat mass [1]. That metabolic work concerns EPO itself; the ARA-290 trial record is the source for the analogue-specific question, and it is a protocol, not a results report.

ARA-290 and diabetic macular oedema

A phase II, prospective, open-label, interventional, single-centre, investigator-led trial examined ARA-290 in diabetic macular oedema in patients with type 1 or type 2 diabetes [3]. The primary objective was to determine whether ARA-290 administered at a daily dose of 4 mg subcutaneously for 12 weeks would have a beneficial effect on the mean change in best corrected visual acuity from baseline to week 12 [3]. As with the other registry entries, this is a description of study design and objective; the evidence block does not supply outcome data.

ARA-290 and cognitive and neural processing of emotion in healthy volunteers

One registered study approached the compound from a neuropsychiatric angle. It notes that studies of EPO have indicated possible antidepressant properties, but that repeated EPO administration may cause serious side-effects such as thrombosis, which limits its usefulness in that context; ARA-290 is described there as a peptide that does not have EPO's effects on blood cells but may still affect brain function [6]. The study was designed to attempt replication of previous findings with a single dose of EPO in healthy volunteers, testing whether a single dose of ARA-290 produces a positive shift in information processing compared with placebo at 7 days post-administration [6]. The population here is healthy volunteers, and the endpoint is cognitive and neural processing of emotion rather than any clinical outcome.

ARA-290 and microglial EPOR signalling in developmental motor deficits

Work in mice has examined the EPO/EPOR axis in microglia. In young mice exposed to multiple sevoflurane anaesthesia, EPOR — described as a microglial receptor associated with phagocytic activity — was significantly downregulated in the medial prefrontal cortex [2]. The authors reported that inhibition of the EPO/EPOR signalling axis led to microglial polarisation, excessive excitatory synaptic pruning, and abnormal fine motor control skills in the anaesthetised mice [2]. The clinical motivation cited in that paper is observational: studies including the Mayo Anesthesia Safety in Kids (MASK) study have found that children undergoing multiple anaesthesia may have a higher risk of fine motor control difficulties, with mechanisms remaining unclear [2]. This is an animal study of receptor biology; it does not administer ARA-290, and it should not be read as evidence of an effect of the compound.

ARA-290 and EPOR-CD131 heterodimer signalling in cardiomyocytes

A related line of work concerns the receptor complex itself. Pegmolesatide, described as a novel long-acting EPO receptor modulator, was studied for its effect on indoxyl sulfate-induced cardiomyocyte hypertrophy, with the authors reporting suppression of EPOR-CD131 heterodimer formation and modulation of the dependent JAK2/STAT3 signalling pathway [9]. The background given is that cardiovascular events remain the leading cause of mortality in chronic kidney disease and that pegmolesatide has shown cardiovascular benefits in clinical studies [9]. This is a different molecule from ARA-290 and is included here only because it bears on the heteromeric receptor pharmacology that the ARA-290 literature invokes [4].

ARA-290 and SIRT1/NF-κB/IL-1β signalling in apical periodontitis

An in vitro study investigated ARA-290 in the context of apical periodontitis, aiming to characterise its protective effects and underlying mechanisms in mitigating pro-inflammatory responses of macrophages, with the authors reporting involvement of the SIRT1/NF-κB/IL-1β pathway [10]. This is a cell-level investigation of inflammatory signalling and is the most mechanistically specific ARA-290 item in the supplied evidence; it is not a clinical finding and does not establish any systemic effect.

ARA-290 in the wider regenerative peptide literature

A narrative review of regenerative peptides relevant to chronic pain management summarises current evidence across a group of compounds including collagen peptides, BPC-157, TB-4, TB-500, GHK-Cu and growth hormone-related peptides [7]. Separately, a review of pharmacological management of diabetic neuropathy describes the cellular triggers of nerve damage — oxidative stress, inflammation and glycation products — and surveys current evidence, clinical positioning and emerging therapeutic targets [8]. Neither review is specific to ARA-290, and neither is used here to support a claim about the compound; they are cited as context for the research area in which the ARA-290 studies sit.

Comparison of the ARA-290 research models in the supplied evidence

Model or populationSettingMechanistic focusSource
Sarcoidosis with small fiber neuropathyRegistered clinical trial, subcutaneous daily for 28 daysInnate repair receptor; anti-apoptotic and anti-inflammatory activity[4]
Prediabetes or drug-naive type 2 diabetesRegistered clinical trialGlucose levels, insulin secretion, insulin sensitivity, cytokines[5]
Type 1 or type 2 diabetes with diabetic macular oedemaPhase II open-label trial, 4 mg subcutaneous daily for 12 weeksBest corrected visual acuity change from baseline[3]
Healthy volunteersRegistered study, single doseCognitive and neural processing of emotion[6]
Macrophages, apical periodontitis contextIn vitroSIRT1/NF-κB/IL-1β pathway[10]
Young mice, multiple sevoflurane exposureAnimalMicroglial EPOR, synaptic pruning, fine motor control[2]

Where the evidence sits

Two points should be stated plainly. First, the ARA-290-specific items in the supplied evidence are predominantly registry records describing study design and rationale rather than published outcome data [3][4][5][6]; the one ARA-290 laboratory study cited is in vitro [10]. Second, the animal and receptor-biology findings cited here concern EPO/EPOR signalling generally or a different EPO receptor modulator, not ARA-290 administration [1][2][9]. The metabolic observations about lipolysis, lipogenic gene expression and fat mass come from work on EPO itself [1], and the microglial findings come from a mouse anaesthesia model [2].

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp